Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 37846000
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G. Tuninetti V, et al. Among authors: carella c. Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032. Cancers (Basel). 2023. PMID: 36831376 Free PMC article.
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Stellato M, Buti S, Maruzzo M, Bersanelli M, Pierantoni F, De Giorgi U, Di Napoli M, Iacovelli R, Vitale MG, Ermacora P, Malgeri A, Maiorano BA, Prati V, Mennitto A, Cavo A, Santoni M, Carella C, Fratino L, Procopio G, Verzoni E, Santini D. Stellato M, et al. Among authors: carella c. Int J Mol Sci. 2023 Jan 6;24(2):1096. doi: 10.3390/ijms24021096. Int J Mol Sci. 2023. PMID: 36674615 Free PMC article.
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, Stellato M, Atzori F, Aieta M, Masini C, Hamzaj A, Ermacora P, Veccia A, Scandurra G, Gamba T, Ignazzi G, Pignata S, Di Napoli M, Lolli C, Procopio G, Pierantoni F, Zonno A, Santini D, Di Maio M; Meet-URO12 Investigators. Vignani F, et al. Among authors: carella c. Eur Urol. 2023 Jan;83(1):82-89. doi: 10.1016/j.eururo.2022.09.025. Epub 2022 Oct 8. Eur Urol. 2023. PMID: 36216658 Clinical Trial.
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi SE, Signori A, Stellato M, Santini D, Maruzzo M, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Fantinel E, Carella C, Procopio G, Milella M, Boccardo F, Fratino L, Sabbatini R, Ricotta R, Panni S, Massari F, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Llaja Obispo MA, Porta C, Buti S, Fornarini G, Banna GL. Rebuzzi SE, et al. Among authors: carella c. Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022. Front Oncol. 2022. PMID: 36212433 Free PMC article.
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, Buti S, Santini D, Carella C, Galli L, Verri E, Ermacora P, Merler S, Masini C, De Vivo R, Milesi L, Spina F, Rizzo M, Sperduti I, Fornarini G, Tortora G. Iacovelli R, et al. Among authors: carella c. Ann Oncol. 2022 Nov;33(11):1179-1185. doi: 10.1016/j.annonc.2022.07.011. Epub 2022 Aug 2. Ann Oncol. 2022. PMID: 35926813 Free article. Clinical Trial.
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.
Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, D'Arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Basso U, et al. Among authors: carella c. Cancers (Basel). 2022 May 4;14(9):2293. doi: 10.3390/cancers14092293. Cancers (Basel). 2022. PMID: 35565422 Free PMC article.
157 results